Endologix Appoints Jeffrey S. Brown as Chief Operations Officer
August 15 2018 - 8:00AM
Business Wire
Endologix, Inc. (Nasdaq:ELGX) (“Endologix” or the “Company”), a
developer and marketer of innovative treatments for aortic
disorders, today announced that it has appointed Jeffrey S. Brown
as the Company’s Chief Operations Officer, effective as of August
13, 2018.
John Onopchenko, Chief Executive Officer of Endologix, Inc.,
said, “I am very excited to have someone with Jeff’s credentials
and industry knowledge joining our executive team. His proven track
record of transformational leadership, operational excellence, and
delivering results will be invaluable to Endologix. We remain
focused on building a cohesive team and a strong culture of
accountability, while continuing to innovate and position the
Company for further operational improvements.”
Mr. Brown brings to Endologix twenty
four years of experience as a General Manager,
Chief Operating Officer, Supply Chain Executive, Sales
Leader, Consultant and Lecturer. Most recently, he was General
Manager of a multi-site joint venture between Johnson & Johnson
and Steris Corporation, where he led significant improvements
across operations, quality, engineering, and supply chain. Prior to
that, he was Chief Operating Officer for Chatham Industries, where
he helped successfully orchestrate a leveraged buyout and
turnaround of the firm. Prior to that, Mr. Brown worked
for five years as General Manager at Boston Scientific Corporation,
where he led a critical site transformation and sat on the global
supply chain management board. Mr. Brown also worked for seven
years as Worldwide Operations Manager at Johnson & Johnson and
for five years leading sterilization operations across
the U.S., EU, and Far East for Haemonetics
Corporation.
Mr. Brown commented, ”I am thrilled to be taking on this
critical leadership role at Endologix, particularly during this
transformational time. I look forward to working with the team to
improve operations and to leverage our talent and innovative
technology, with the ultimate goal of delivering superior products
and services to our patients.”
Mr. Brown earned his MBA from Babson College, Wellesley, MA and
his Bachelor of Science in Microbiology from University of New
Hampshire, Durham, NH.
About Endologix, Inc.
Endologix, Inc. develops and manufactures minimally invasive
treatments for aortic disorders. The Company's focus is
endovascular stent grafts for the treatment of abdominal aortic
aneurysms (AAA). AAA is a weakening of the wall of the aorta, the
largest artery in the body, resulting in a balloon-like
enlargement. Once AAA develops, it continues to enlarge and, if
left untreated, becomes increasingly susceptible to rupture. The
overall patient mortality rate for ruptured AAA is approximately
80%, making it a leading cause of death in the United States. For
more information, visit www.endologix.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180815005135/en/
Investors:Endologix, Inc.Vaseem Mahboob, 949-595-7200CFO
Endologix (NASDAQ:ELGX)
Historical Stock Chart
From Sep 2024 to Oct 2024
Endologix (NASDAQ:ELGX)
Historical Stock Chart
From Oct 2023 to Oct 2024